Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
2.545
-0.005 (-0.20%)
At close: Nov 22, 2024, 4:00 PM
2.450
-0.095 (-3.73%)
After-hours: Nov 22, 2024, 7:06 PM EST
CELZ Revenue
Creative Medical Technology Holdings had revenue of $11.00K in the twelve months ending September 30, 2024, down -55.28% year-over-year. In the year 2023, Creative Medical Technology Holdings had annual revenue of $9.00K, down -89.84%.
Revenue (ttm)
$11.00K
Revenue Growth
-55.28%
P/S Ratio
n/a
Revenue / Employee
$2,750
Employees
4
Market Cap
4.45M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCELZ News
- 10 days ago - Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Provides Corporate Update - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin - GlobeNewsWire
- 9 months ago - Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access - Business Wire
- 9 months ago - Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy - Business Wire
- 1 year ago - Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain - Accesswire
- 1 year ago - Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain - PRNewsWire